In a complimentary series of experiments, we evaluated the immune transcriptional signatures of spontaneous UPS (n = 3), transplanted UPS (n = 3), and transplanted UPS treated with an intra-tumoural dose of a stimulator of interferon genes (STING) agonist, DMXAA (18mg/kg, Sigma) (‘inflamed sarcoma’, n = 3) using the NanoString® Pan Cancer Immune Panel. The gene discussed is STING1; the disease is sarcoma.